Latest Insider Transactions at Immunovant, Inc. (IMVT)
This section provides a real-time view of insider transactions for Immunovant, Inc. (IMVT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Immunovant, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Immunovant, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 18
2023
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
3,395
-0.27%
|
$50,925
$15.27 P/Share
|
|
Apr 17
2023
|
Jay S Stout Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+50.0%
|
-
|
|
Apr 12
2023
|
Douglas J. Hughes Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,523
+9.92%
|
-
|
|
Apr 12
2023
|
Atul Pande Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,523
+11.59%
|
-
|
|
Apr 12
2023
|
George V Migausky Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,523
+9.27%
|
-
|
|
Apr 12
2023
|
Andrew J. Fromkin Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,523
+11.03%
|
-
|
|
Apr 12
2023
|
Julia G. Butchko Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
100,188
+18.84%
|
-
|
|
Apr 12
2023
|
Frank Torti Director |
BUY
Grant, award, or other acquisition
|
Direct |
121,916
+19.13%
|
-
|
|
Apr 12
2023
|
William L. Macias Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
87,664
+20.0%
|
-
|
|
Apr 12
2023
|
Eva Renee Barnett Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
87,664
+19.76%
|
-
|
|
Apr 12
2023
|
Mark S. Levine Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
87,664
+20.82%
|
-
|
|
Apr 12
2023
|
Peter Salzmann Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
243,832
+16.46%
|
-
|
|
Feb 02
2023
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
537
-0.2%
|
$9,666
$18.24 P/Share
|
|
Jan 26
2023
|
Mark S. Levine Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,156
-3.97%
|
$182,808
$18.51 P/Share
|
|
Jan 11
2023
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
44,568
-7.24%
|
$668,520
$15.93 P/Share
|
|
Jan 11
2023
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,510
-0.83%
|
$67,650
$15.95 P/Share
|
|
Jan 11
2023
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
60,490
-7.72%
|
$907,350
$15.98 P/Share
|
|
Jan 11
2023
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
4,021
-0.4%
|
$64,336
$16.8 P/Share
|
|
Oct 21
2022
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
341
-0.11%
|
$3,069
$9.67 P/Share
|
|
Oct 13
2022
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,793
-0.28%
|
$25,137
$9.18 P/Share
|
|
Oct 13
2022
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
928
-0.24%
|
$8,352
$9.18 P/Share
|
|
Oct 11
2022
|
Eva Renee Barnett Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
12,500
-4.38%
|
$112,500
$9.44 P/Share
|
|
Oct 06
2022
|
Roivant Sciences Ltd. |
BUY
Open market or private purchase
|
Direct |
416,667
+0.56%
|
$2,500,002
$6.0 P/Share
|
|
Sep 30
2022
|
Atul Pande Director |
BUY
Open market or private purchase
|
Indirect |
15,000
+42.86%
|
$75,000
$5.6 P/Share
|
|
Sep 29
2022
|
Frank Torti Director |
BUY
Open market or private purchase
|
Direct |
20,000
+4.84%
|
$100,000
$5.81 P/Share
|
|
Sep 28
2022
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,605
-0.16%
|
$6,420
$4.67 P/Share
|
|
Sep 28
2022
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
535
-0.14%
|
$2,140
$4.67 P/Share
|
|
Aug 30
2022
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,644
-0.16%
|
$8,220
$5.83 P/Share
|
|
Aug 30
2022
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
548
-0.14%
|
$2,740
$5.83 P/Share
|
|
Aug 17
2022
|
Frank Torti Director |
BUY
Grant, award, or other acquisition
|
Direct |
225,632
+37.67%
|
-
|
|
Aug 17
2022
|
Douglas J. Hughes Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,059
+17.22%
|
-
|
|
Aug 17
2022
|
George V Migausky Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,059
+16.07%
|
-
|
|
Aug 17
2022
|
Atul Pande Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,059
+20.24%
|
-
|
|
Aug 17
2022
|
Andrew J. Fromkin Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,059
+19.22%
|
-
|
|
Aug 17
2022
|
Peter Salzmann Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
451,264
+31.01%
|
-
|
|
Aug 17
2022
|
Eva Renee Barnett Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,816
+28.33%
|
-
|
|
Aug 17
2022
|
Julia G. Butchko Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,816
+22.26%
|
-
|
|
Aug 17
2022
|
William L. Macias Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,816
+26.78%
|
-
|
|
Aug 17
2022
|
Mark S. Levine Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
112,816
+30.6%
|
-
|
|
Jul 27
2022
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,528
-0.28%
|
$6,112
$4.27 P/Share
|
|
Jul 27
2022
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
510
-0.18%
|
$2,040
$4.27 P/Share
|
|
Jul 22
2022
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
322
-0.16%
|
$1,288
$4.7 P/Share
|
|
Jun 29
2022
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
460
-0.16%
|
$1,840
$4.02 P/Share
|
|
Jun 29
2022
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,376
-0.25%
|
$5,504
$4.02 P/Share
|
|
May 24
2022
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,471
-0.26%
|
$4,413
$3.79 P/Share
|
|
May 24
2022
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
492
-0.17%
|
$1,476
$3.79 P/Share
|
|
Apr 27
2022
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,622
-0.29%
|
$6,488
$4.72 P/Share
|
|
Apr 27
2022
|
Julia G. Butchko Chief Development Officer |
SELL
Open market or private sale
|
Direct |
541
-0.19%
|
$2,164
$4.72 P/Share
|
|
Apr 19
2022
|
William L. Macias Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,392
-0.71%
|
$5,568
$4.98 P/Share
|
|
Mar 24
2022
|
Peter Salzmann Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
19,227
-3.33%
|
$96,135
$5.9 P/Share
|